The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
暂无分享,去创建一个
J. Elston | R. Taylor | R S Taylor | J Elston
[1] P Wainwright,et al. Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.
[2] H. Williams,et al. Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. , 2006, Health technology assessment.
[3] C. Bull,et al. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. , 2005, Health technology assessment.
[4] M. McDonagh,et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. , 2000, Health technology assessment.
[5] A. Silman,et al. Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. , 2004, Health technology assessment.
[6] M. Pitt,et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. , 2008, Health technology assessment.
[7] M. Sculpher,et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. , 2006, Health technology assessment.
[8] S. Bryan,et al. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. , 2002, Health technology assessment.
[9] K Tolley,et al. The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature. , 2000, Health technology assessment.
[10] S. Paisley,et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. , 2003, Health technology assessment.
[11] P Barton,et al. Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. , 2005, Health technology assessment.
[12] A. O'Hagan,et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. , 2006, Health technology assessment.
[13] P. Tugwell,et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. , 2007, The Journal of rheumatology.
[14] D G Altman,et al. Indirect comparisons of competing interventions. , 2005, Health technology assessment.
[15] S. Palmer,et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. , 2006, Health Technology Assessment.
[16] P. Royle,et al. Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. , 2005, Health technology assessment.
[17] R. Fitzpatrick,et al. Issues in methodological research: perspectives from researchers and commissioners. , 2001, Health technology assessment.
[18] R Garside,et al. Systematic review of endoscopic sinus surgery for nasal polyps. , 2003, Health technology assessment.
[19] J Shepherd,et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.
[20] T. Skinner,et al. Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. , 2001, Health technology assessment.
[21] M. Pitt,et al. The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. , 2005, Health technology assessment.
[22] H. Williams,et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. , 2005, Health technology assessment.
[23] C. Normand,et al. A systematic review of the role of bisphosphonates in metastatic disease. , 2004, Health technology assessment.
[24] M. Petticrew,et al. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. , 1998, Health technology assessment.
[25] D. Lamping,et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. , 2005, Health technology assessment.
[26] T. Peters,et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.
[27] R. Davey,et al. Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis. , 2005, Health Technology Assessment.
[28] M. Pitt,et al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. , 2006, Health technology assessment.
[29] S. Ebrahim,et al. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. , 2004, Health technology assessment.
[30] M. Mugford,et al. Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. , 2000, Health technology assessment.
[31] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] F. Cowan,et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. , 2000, Health technology assessment.
[33] R. Collins,et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. , 2005, Health technology assessment.
[34] A. Grant,et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence. , 2003, Health technology assessment.
[35] S. Wessely,et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. , 2002, Health technology assessment.
[36] C. Fowler,et al. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. , 2005, Health technology assessment.
[37] A. Round,et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. , 2004, Health technology assessment.
[38] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[39] P F Sharp,et al. The value of digital imaging in diabetic retinopathy. , 2003, Health technology assessment.
[40] R. Kay. Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.
[41] K. Payne,et al. Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial. , 2002, Health technology assessment.
[42] A Haycox,et al. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. , 2003, Health technology assessment.
[43] Claudia Wild,et al. BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS , 2002, International Journal of Technology Assessment in Health Care.
[44] P. Tappenden,et al. Methodological issues in the economic analysis of cancer treatments. , 2006, European journal of cancer.
[45] A E Ades,et al. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. , 1999, Health technology assessment.
[46] M Forshaw,et al. A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment. , 1997, Health technology assessment.
[47] E. Loveman,et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. , 2006, Health technology assessment.
[48] J Raftery,et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. , 2005, Health technology assessment.
[49] K. Morgan,et al. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. , 2004, Health technology assessment.
[50] T Tillin,et al. Outcomes of electrically stimulated gracilis neosphincter surgery. , 2005, Health technology assessment.
[51] G. Guyatt,et al. Users' guides to the medical literature. , 1993, JAMA.
[52] M Sculpher,et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. , 2005, Health technology assessment.
[53] E. Murphy,et al. Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.
[54] S. Stewart-Brown,et al. The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children. , 2005, Health technology assessment.
[55] R. Milne,et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. , 2002, Health technology assessment.
[56] A. Knowles. DIABETIC FOOT ULCERATION , 1996 .
[57] R. Milne,et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. , 2002, Health technology assessment.
[58] L. Sharples,et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. , 2006, Health technology assessment.
[59] R. Jordan,et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. , 2000, Health technology assessment.
[60] A. Culyer,et al. False-negative results in screening programmes: systematic review of impact and implications. , 2000, Health technology assessment.
[61] P. Bower,et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. , 2000, Health technology assessment.
[62] A. Culyer,et al. Newborn screening for inborn errors of metabolism: a systematic review. , 1997, Health technology assessment.
[63] B. Cooper,et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. , 2003, Health technology assessment.
[64] P Sutcliffe,et al. Health technology assessment. , 1986, Israel journal of medical sciences.
[65] M Knapp,et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. , 2005, Health technology assessment.
[66] M. Sculpher,et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. , 2005, Health technology assessment.
[67] S. Walters,et al. Costs and benefits of community postnatal support workers: a randomised controlled trial. , 2000, Health technology assessment.
[68] M. Pitt,et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. , 2007, Health technology assessment.
[69] J Raftery,et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.
[70] P. Royle,et al. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. , 2003, Health technology assessment.
[71] M J Daniels,et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group , 1998, AIDS.
[72] M Sculpher,et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.
[73] P Sutcliffe,et al. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. , 2006, Health technology assessment.
[74] A. Glenny,et al. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials , 1998, Health technology assessment.
[75] C. Normand,et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. , 2000, Health technology assessment.
[76] C. Weir,et al. Statistical evaluation of biomarkers as surrogate endpoints: a literature review , 2006, Statistics in medicine.
[77] J Gabbay,et al. Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach. , 2004, Health technology assessment.
[78] S. Mason,et al. EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy. , 2004, Health technology assessment.
[79] A. Thompson,et al. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. , 2004, Health technology assessment.
[80] F. Song,et al. Evaluating non-randomised intervention studies. , 2003, Health technology assessment.
[81] J. Raftery,et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. , 2006, Health technology assessment.
[82] M Sculpher,et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.
[83] C. Clar,et al. Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation. , 2005, Health technology assessment.
[84] C. Eiser,et al. Quality-of-life measures in chronic diseases of childhood. , 2001, Health technology assessment.
[85] C. Beverley,et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. , 2005, Health technology assessment.
[86] R. Murray,et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. , 2006, Health technology assessment.
[87] M. Mugford,et al. The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas. , 2004, Health technology assessment.
[88] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[89] G. ter Riet,et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. , 2008, Health technology assessment.
[90] J. Wight,et al. Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.
[91] Geert Molenberghs,et al. Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.
[92] Jennifer A. Roberts,et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. , 2006, Health technology assessment.
[93] P. Roderick,et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. , 2003, Health Technology Assessment.
[94] M. Westwood,et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. , 2004, Health technology assessment.
[95] Z Krukowski,et al. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation. , 2006, Health technology assessment.
[96] M J Buxton,et al. Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.
[97] J Nicholl,et al. Routine preoperative testing: a systematic review of the evidence. , 1997, Health technology assessment.
[98] S. Stearns,et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. , 2003, Health technology assessment.
[99] David R. Jones,et al. A systematic review of discharge arrangements for older people. , 2002, Health technology assessment.
[100] D. Spiegelhalter,et al. Consensus development methods, and their use in clinical guideline development. , 1998, Health technology assessment.
[101] M. Drummond,et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. , 2006, Health technology assessment.
[102] N. Waugh,et al. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. , 2000, Health technology assessment.
[103] S. Paisley,et al. Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. , 2006, Health technology assessment.
[104] A. Culyer,et al. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. , 1998, Health technology assessment.
[105] T. Sheldon,et al. What role for statins? A review and economic model. , 1999, Health technology assessment.
[106] P. Barry,et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. , 2001, Health technology assessment.
[107] S. Bryan,et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. , 2006, Health technology assessment.
[108] Paul M Ridker,et al. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. , 2006, JAMA.
[109] T P Klassen,et al. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. , 2003, Health technology assessment.
[110] A. Culyer,et al. Liquid-based cytology in cervical screening: a rapid and systematic review. , 2000, Health technology assessment.
[111] J Gabbay,et al. 'Early warning systems' for identifying new healthcare technologies. , 1999, Health technology assessment.
[112] V Torri,et al. Beware of Surrogate Outcome Measures , 1996, International Journal of Technology Assessment in Health Care.
[113] David R. Jones,et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. , 2003, Health technology assessment.
[114] C. McCollum,et al. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. , 2006, Health technology assessment.
[115] A Haycox,et al. Coronary artery stents: a rapid systematic review and economic evaluation. , 2004, Health technology assessment.
[116] Richard Pazdur,et al. End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] E Berry,et al. The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review. , 2002, Health technology assessment.
[118] D. Symmons,et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. , 2006, Health technology assessment.
[119] C Fraser,et al. Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation. , 2005, Health technology assessment.
[120] M Sculpher,et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. , 2004, Health technology assessment.
[121] R Garside,et al. The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling. , 2004, Health technology assessment.
[122] R. Milne,et al. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. , 2000, Health technology assessment.
[123] N. Waugh,et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.
[124] P. Whiting,et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. , 2001, Health technology assessment.
[125] David R. Jones,et al. Methods for the analysis of quality-of-life and survival data in health technology assessment. , 1999, Health technology assessment.
[126] J Cowan,et al. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. , 2003, Health technology assessment.
[127] M Sculpher,et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.
[128] Keogh-Brown,et al. Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts , 2006 .
[129] M. Connock,et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. , 2006, Health technology assessment.
[130] M. Gulliford,et al. Monitoring blood glucose control in diabetes mellitus: a systematic review. , 2000, Health technology assessment.
[131] D. Symmons,et al. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. , 2005, Health technology assessment.
[132] A. Grant,et al. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. , 2005, Health technology assessment.
[133] Aloka G Chakravarty,et al. Regulatory Aspects in Using Surrogate Markers in Clinical Trials , 2005, The Evaluation of Surrogate Endpoints.
[134] Simon Finfer,et al. SAFE (The Saline versus Albumin Fluid Evaluation) 試験 , 2006 .
[135] N. Waugh,et al. Screening for gestational diabetes: a systematic review and economic evaluation. , 2002, Health technology assessment.
[136] K. Jolly,et al. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. , 2000, Health technology assessment.
[137] C. Czoski-Murray,et al. Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and pre-registration house officers in pre-operative assessment in elective general surgery. , 2001, Health technology assessment.
[138] P Barton,et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. , 2006, Health technology assessment.
[139] J. Caro,et al. Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care , 2001, Neurology.
[140] R Garside,et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. , 2005, Health technology assessment.
[141] A. Bagnall,et al. Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review. , 2003, Health technology assessment.
[142] E De Nigris,et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. , 2005, Health technology assessment.
[143] M. Knapp,et al. Home treatment for mental health problems: a systematic review. , 2001, Health technology assessment.
[144] J A Kanis,et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. , 2002, Health technology assessment.
[145] J. Shepherd,et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. , 2006, Health technology assessment.
[146] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[147] M. Smith,et al. Systematic review of endoscopic ultrasound in gastro-oesophageal cancer. , 1998, Health Technology Assessment.
[148] J Chilcott,et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. , 2003, Health technology assessment.
[149] L. Sharples,et al. Evaluation of the ventricular assist device programme in the UK. , 2006, Health technology assessment.
[150] P. Royle,et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. , 2002, Health technology assessment.
[151] J. Dretzke,et al. Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus. , 2004, Health technology assessment.
[152] M K Campbell,et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.